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Abstract
Serum  thyroglobulin  (Tg)  and  Tg  antibody  (TgAb)  levels,  together  with  neck
ultrasonography  and  131I  whole-body  scintigraphy  (WBS),  are  diagnostic  tools  for
postoperative  follow-up  of  patients  with  differentiated  thyroid  carcinoma  (DTC).
Generally, good correlation is seen between Tg and WBS in follow-up studies for DTC
after  thyroid remnant ablation.  Undetectable serum Tg with negative WBS results
suggests complete remission, whereas detectable, or elevated, serum Tg is associated
with radioiodine uptake in local or distant metastases. Patients with thyroid cancer
cells lacking radioiodine uptake despite an elevated serum Tg level have been referred
to as WBS-negative, Tg-positive patients, who represent 10–15% of cases. 18F-FDG PET
(FDG-PET) scanning should be considered in high-risk DTC patients with negative
WBS and positive Tg. The preferred therapeutic hierarchy for Tg-positive and WBS-
negative  metastases  is  surgical  excision  of  loco-regional  disease,  131I  therapy  for
radioiodine-responsive  disease,  external  beam  radiation,  TSH  suppression,  and
systemic therapy with kinase inhibitors. If FDG-PET diagnostic results are negative,
one course of 131I treatment may be considered in high-risk patients and individual‐
ized. No further 131I therapy is indicated for patients with a negative post-therapy WBS.
Keywords: differentiated thyroid carcinoma, thyroglobulin, whole-body scan, radio‐
iodine
1. Introduction
Serum thyroglobulin (Tg) is a tissue-specific 660 kDa protein that serves as a precursor in
thyroid  hormone  biosynthesis  [1].  It  is  synthesized  by  both  thyroid  follicular  cells  and
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differentiated cancer cells. Monitoring of serum Tg and Tg antibody (TgAb) levels, together
with neck ultrasonography and 131I whole-body scintigraphy (WBS), is used as a diagnostic
tool in postoperative follow-up for patients with differentiated thyroid carcinoma (DTC) [2].
Generally, good correlation is seen between Tg and WBS in follow-up studies for DTC after
thyroid remnant ablation [3]. Undetectable serum Tg with negative WBS results suggests
complete remission, whereas detectable, or elevated, serum Tg is associated with radioio‐
dine uptake in local or distant metastases. Patients with thyroid cancer cells lacking radioio‐
dine uptake despite their elevated serum Tg level have been referred to as WBS-negative, Tg-
positive patients [3]. The possible explanations and management for the discordant finding
are discussed in this chapter.
2. Description of DTC with elevated Tg level and negative WBS
Tg is a thyroid tissue-specific antigen produced by thyroid follicular cells. Its measurement is
the best sign of detecting thyroid tissue, including metastasis of DTC. After a total thyroidec‐
tomy and radioiodine ablation, any detactable Tg is interpreted as recurrent disease. Although
it is a highly sensitive and specific marker of recurrence, Tg measurement cannot locate the
recurrent DTC [4, 5]. Imaging technologies, including WBS, ultrasonography, computed
tomography (CT), and magnetic resonance imaging (MRI), play great role in locating the DTC
metastases. Tg is a very sensitive marker for thyroid malignancy, and it is not uncommon to
encounter patients who show at initial follow-up, detectable Tg levels with negative imaging
studies [6]. Patients with thyroid cancer cells lacking radioiodine uptake on WBS despite their
elevated serum Tg level have been referred to as WBS-negative, Tg-positive patients; they
represent 10–15% of patients with DTC at follow-up. Due to its inferior sensitivity, the routine
WBS has been supplanted by serum Tg and neck ultrasonography, CT and/or MRI. The reasons
for raised Tg and negative scan results have been summarized previously [7]. The elevated Tg
level and negative WBS are classified into “true-negative WBS with false-positive Tg” and
“false-negative WBS and true-positive Tg.” Because of the low sensitivity of WBS, cervical
ultrasonography plays more important role in the follow-up of DTC patients. Therefore, a new
challenging scenario has emerged: the ultrasonography-negative, Tg-positive patient [8].
2.1. True-iodine negative and false-positive Tg
(1) Tg assays interference
The possibility of a false-positive serum Tg because of assay interference is rare but should
be considered. And serum Tg has a lower false-negative rate than WBS after stimulation
of thyroid stimulating hormone (TSH) either by thyroid hormone withdrawal or by
recombinant human thyroid stimulating hormone (rhTSH) [9–13]. Optimal follow-up
requires remnant ablation, and TSH-stimulated Tg testing [4]. The sensitivities and
specificities of various Tg assays vary widely between laboratories, even with the use of
an international standard (CRM 457) [14, 15], which have potential to disrupt serial
monitoring and prompt inappropriate clinical decisions [9]. Additionally, undetectable
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serum Tg became detectable in a significant percentage of DTC patients by changing
assays [16–18]. Therefore, Tg should be dynamically monitored using the same assay
performed in the same laboratory. If possible, patient’s serum is frozen and saved for
recovery test to assess the reliability of Tg when there is a change in Tg assay [19]. As the
sensitivity of commercially available Tg assays improves, TSH-stimulated Tg may not be
necessary in patients with low and intermediate risk of recurrence [9].
(2) Circulating TgAb and HAb interferences
A major problem that hampers accurate Tg measurement is the interference by TgAb and
HAb resulting in either an under- or overestimation of the serum Tg concentration [19–
21]. Depending on the population studied and the assay used, up to 25–30% of patients
with DTC have a positive test for TgAb at the time of initial diagnosis [22, 23]. In addition,
a small to moderate percentage of patients (in the literature ranging from <1 to >10%) show
HAb interference in Tg measurement, an integral tool in the management of DTC patients.
These antibodies typically falsely lower the Tg value in immuno-chemiluminometric
assays and immuno-radiometric assays, while raising the value in radio-immunoassay.
Therefore, TgAb should be measured in the same serum sample taken for Tg assay [15,
24]. Although for clinical purposes the measurement of Tg and TgAb before thyroidec‐
tomy for a suspected or proven DTC is not recommended, a pre-thyroidectomy Tg and
TgAb measurement might be used as an “in vivo” recovery test in order to assess the
reliability of Tg for use as a postoperative tumor marker [19, 25]. In DTC patients, the limit
of quantitation (LoQ) of a given TgAb assay should be regarded as the upper normal limit
for the presence of TgAb [25]. Thyroid laboratories should report two reference ranges
for TgAb: one based on the presence of TgAb in a population free of thyroid disease, which
should be used for the diagnosis of autoimmune thyroid disorders, and the LoQ which
should be used as the upper normal limit in DTC patients. A proposed algorithm for
follow-up in TgAb-positive patients with DTC was listed in Figure 1 from Verburg et al.
[25].
Persistence of Tg-Ab for more than 1 year after thyroidectomy and 131I ablation probably
indicates the presence of residual thyroid tissue and possibly and/or DTC recurrence [22,
24, 26]. A recent study also showed that TSH receptor mRNA accurately predicted disease
status in 68% of DTC patients [27].
(3) Benign sources of Tg secretion
Apart from their ability to interfere with Tg assays, benign lesions (possibly with foci of
thyroiditis) in persistent residual thyroid tissue or non-thyroidal tissue producing Tg may
also result in false-positive Tg in DTC patients. However, residual occult disease is usually
the source of post-operative Tg elevations [28–30]. Rarely, TSH-stimulated thymus may
produce Tg [6].
Rarely, ectopic thyroid tissue may persist at the base of the tongue or, more often, at any other
position along the thyroglossal tract, with the potential to elevate serum Tg levels. The
thyroglossal tract is the most common location for ectopic thyroid tissue. This tissue retains




not only the ability to concentrate iodine, but also to produce Tg and release it into the
bloodstream [28, 31, 32]. The iodine metabolism-related proteins such as human sodium/
iodide symporter (hNIS) [33], TSH receptor at both mRNA and protein level [6] are present in
non-thyroidal tissues, including the thymus. Usually, these functions are dormant, but they
Figure 1. The algorithm for treatment and follow-up in Tb-Ab positive differentiated thyroid cancer patients from Ver‐
burg et al. [25].
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may be activated by TSH stimulation [34]. Interestingly, these extra-thyroidal foci may be
resistant to multiple 131I treatments [28, 31, 32]. In a series of 548 consecutive diagnostic WBS,
ectopic thyroid tissue in the tongue or in the upper part of the thyroglossal duct was visualized
in five patients (0.9%) [28]. However, in another study of 60 patients, 19/60 (31.7%) had a linear
or focal radioactivity at the superior midline of the neck, suggesting thyroglossal duct remnant
[29]. The absence of metastases in the thymus despite high Tg levels was confirmed in five
cases [33, 35]. Rare cases of thyroid tissue ectopy has been summarized in some locations such
as struma ovarii, the heart (struma cordis), the submandibular, parotid and salivary glands,
the duodenum, the adrenal glands, the liver and gallbladder, the pancreas, the axilla, and iris
of the eye [6].
In summary, interference with Tg assays by TgAb and HAb, benign lesions (possibly contain‐
ing thyroiditis) in persistent residual thyroid tissue or nonthyroidal tissue producing Tg may
also result in false-positive Tg in DTC patients.
2.2. False-negative WBS and true-positive Tg
The possible causes of false-negative WBS are mentioned below.
(1) Defect of iodine-trapping mechanism such as acquired inactivation mutation of NIS,
TPO gene, pendrin, and TSHR
Thyroid hormone synthesis starts with the active uptake of iodine from the circulation via
NIS. This process, known as iodine trapping, is stimulated directly by TSH and more
circuitously by iodine deficiency. Other proteins, including TPO, TSHR, and pendrin, also
play an important role in the thyroid metabolism of iodine. Any defect in NIS, TPO, Tg,
and TSHR will contribute to false-negative WBS [7].
(2) De-differentiation of tumor such that it can still produce Tg but has lost its iodine-
trapping ability
Various molecular changes within papillary thyroid cancer cells, such as RET/PTC
rearrangements, RAS and BRAF mutations [36], β-catenin mutations, PAX8/PPARã,
histone acetylation factors involved in angiogenesis including overexpression of vascular
endothelial growth factor (VEGF) and EGF receptor (EGFR) underlie the loss of iodide
uptake ability [37]. The dedifferentiated DTC cells lost the ability to concentrate iodine
but may retain Tg synthesizing capability [3, 7], which underlines the phenomenon of Tg-
positive and WBS-negative lesions.
(3) Dispersed microscopic metastases, which are too small to be visualized
(4) Improper patient preparation before WBS
When it is determined that an elevation of Tg is real, if WBS is negative, false-negative scan
such as stable iodine contamination and inadequate TSH elevation should be considered [7].
TSH levels should be elevated to at least 30 mIU/L before concluding that a negative WBS is
meaningful. This can be achieved either by withdrawal of thyroxine or by rhTSH administra‐
tion. rhTSH is as effective as thyroid hormone withdrawal on 131I thyroid remnant ablation for




DTC patients with significant benefits in decreased whole-body radiation exposure and health-
related quality of life [38, 39]. A summary of appropriate patient preparation for WBS in the
hypothyroid state is presented in Table 1 from Ma et al. [7].
Withdrawal of L-T4 for 4–6 weeks or of triiodothyronine for 2 weeks.
A strict low-iodine diet (50 g iodine per day) followed for 7–14 days before WBS and continuing throughout period of
imaging.
Avoidance of iodine-containing medications (e.g., iodinated contrast medium, amiodarone, betadine), iodine-rich
foods (e.g., kelp), and possible additives of iodine in vitamin and electrolyte supplements.
TSH > 30 mIU/L.
A mild laxative sometimes administered on the evening before WBS to simplify image interpretation.
Information relating to patient’s compliance with low-iodine diet, TSH level, history of thyroid hormone withdrawal,
measurement of Tg, history of prior administration of contrast medium or iodine-containing drugs (e.g., amiodarone),
menstrual history/pregnancy test, nursing/lactation history, etc.
Measurement of urinary iodine in doubtful cases to rule out iodine contamination; repeated WBS 4–6 weeks after
iodine depletion regimen such as diuretic program.
Rule out women with pregnancy and breast feeding.
Table 1. A summary of appropriate patient preparation for WBS from reference by Ma et al.
3. Management of DTC patients with positive Tg and negative WBS
3.1. Other diagnostic modalities for DTC in this setting
In the clinical setting, the precise location of WBS-negative recurrent DTC is mandatory
because surgery is the only curative treatment option and metastases that are unable to
concentrate 131I are associated with more aggressive clinical behavior [40]. Cervical ultraso‐
nography, CT and MRI, 124I PET/CT have limited roles in the diagnosis of DTC metastases with
positive Tg and negative WBS. Non-iodine imaging agents—such as 201Tl, 99mTc-sestamibi,
99mTc-tetrofosmin, somatostatin receptor (SRS) scan have reasonable accuracy [41]. However,
they have been replaced by 18F-FDG in the follow-up algorithm of DTC patients with positive
Tg and negative WBS.
(1) Cervical ultrasonography
Cervical ultrasonography has high sensitivity in detecting recurrence in the thyroid bed
and nodal metastases of DTC in the neck [42, 43]. It has been used as first-line diagnostic
imaging in DTC follow-up [44, 45]. However, neck ultrasonography has limitations: one
is that it does not reveal DTC recurrences in other body sites. It is also difficult for cervical
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ultrasonography to differentiate scar tissue and locally recurring fibrosis and between
nonspecific nodal enlargements and nodal metastases [46]. Therefore, the other limitation
of ultrasonography is the low specificity in DTC patients of altered anatomy after thyroid
surgery.
(2) CT and MRI
In patients with elevated or rising Tg or TgAb and no evidence of disease on neck
ultrasonography or WBS (if performed), CT imaging of the neck and chest should be
considered [47]. Diagnostic CT scan may complement neck ultrasonography for the
detection of macrometastases in the central compartment, in the mediastinum and behind
the trachea [48–50], and is the most sensitive tool for the detection of micro-metastases in
the lungs. MRI has also been advocated for imaging the neck and the mediastinum. It is
performed without and with injection of gadolinium chelate as contrast medium and does
not require any injection of iodine contrast medium. Brain and skeletal MRI and/or CT,
or abdominal MRI may be performed in high-risk DTC patients with elevated Tg (gener‐
ally >10 ng/mL) and negative WBS or ultrasonography, who have systemic symptoms
related to those organs, or who will have 131I therapy and may be at risk for complications
of tumor swelling [51]. MRI is less sensitive than CT scan for the detection of lung
micronodules [47].
(3) 18F-FDG-PET/CT or PET/MRI
The iodine-negative DTC lesions were found to have increased expression of the glucose
transporter-1, and often have FDG uptake [52]. Therefore, 18F-FDG-PET is particularly
useful in the detection of recurrent or metastatic DTC in patients with positive Tg and
negative WBS, allowing detection of metastases not detected by other imaging modalities
[53]. In a recent meta-analysis, the combined sensitivity and specificity for FDG-PET/CT
were 93 and 81%, respectively [54].
Factors influencing PET/CT sensitivity include tumor de-differentiation, larger tumor
burden and to a lesser extent, TSH stimulation [47]. PET is more sensitive in patients with
an aggressive histological subtype, including poorly differentiated, tall cell, and Hürthle
cell thyroid cancer. The sensitivity of PET (ranging from less than 10–30%) is low in
patients with a TSH-stimulated Tg < 10 ng/mL. It is therefore recommended to consider
18F-FDG-PET only in DTC patients with a stimulated Tg level ≥10 ng/mL [47]. A meta-
analysis of seven prospective controlled clinical trials indicated that FDG-PET under TSH
stimulation either by thyroid hormone withdrawal or by rhTSH had slightly improved
diagnostic performance in detecting Tg-positive and WBS-negative DTC lesions. FDG-
PET/CT is useful in staging, response assessment after chemotherapy, targeted therapies,
or radiotherapy and prognostic assessment for patients with cancer [55]. Therefore, PET/
CT imaging should be performed as first-line, with empiric 131I treatment being considered
only for those patients with no detectable FDG uptake [51]. PET/CT can also identify
lesions with high FDG uptake (SUV) that may be more aggressive and should have multi-
targeted kinase inhibitors or close monitoring. A study observed that elevated Tg, but
normal PET exists as a definitive entity in DTC. Positive Tg with negative PET was




regarded as a favorable prognostic indicator to predict symptom-free status during the
follow-up period [56].
However, false positives occur with PET imaging with or without TSH stimulation [50].
The frequency of false-positive lesions varies among series from 0 to 39%, and this high
number justifies a fine-needle aspiration (FNA) biopsy with cytology and Tg measure‐
ment in the aspirate fluid in cases where surgery is planned, based on PET results.
FDG-PET/CT is useful in staging, response assessment after chemotherapy, targeted
therapies, or radiotherapy and prognostic assessment for patients with cancer [55].
PET/CT imaging is more sensitive and should be performed as first-line, with empiric
131I treatment being considered only for those patients with no detectable FDG uptake [51].
PET/CT can also identify lesions with high FDG uptake (SUV) that may be more aggressive
and should have multi-targeted kinase inhibitors or close monitoring. A study observed
that elevated Tg, but normal PET exists as a definitive entity in DTC. Positive Tg with
negative PET was regarded as a favorable prognostic indicator to predict symptom-free
status during the follow-up period [56].
(4) 124I PET/CT
124I emits positrons, allowing PET/CT imaging in DTC patients. It is used as for dosimetry
and also as a diagnostic tool to localize DTC metastases. 124I PET/CT accurately measures
the volume, uptake, and half-life of 124I in each DTC lesion, therefore permitting a reliable
individual dosimetric assessment for DTC metastases [47]. 124I-PET has higher sensitivity
in detecting the residual thyroid tissue and/or DTC metastases than that of WBS (99% vs.
66%) [57–61]. The combination of 124I and FDG-PET/CT affords a valuable diagnostic
method that can be used to make therapeutic decisions in patients with positive Tg and
negative WBS [57, 61]. 124I-PET/CT with thyroid hormone withdrawal was found to detect
significantly more foci of metastases of DTC [59]. However, it is unclear whether and to
what extent patient preparation with rhTSH rather than thyroid hormone withdrawal
affects the diagnostic accuracy of 124I PET/CT [57]. 124I is not yet widely available for clinical
use and is primarily a research tool at this time.
(5) Somatostatin receptor scan (SRS)
Thyroid tumors are known to express SRS, and therefore, 111In-pentetreotide (somatostatin
analog) can visualize non-iodine avid DTC metastases with high concentration of SRS. A
case of negative WBS recurrent metastatic papillary thyroid carcinoma with positive 111In-
pentetreotide scan was reported [62]. Technetium-99m labeled somatostatin analog, 99mTc-
Hynic-TOC scintigraphy had a sensitivity of 88.46% (23/26), specificity of 100% (2/2), and
an accuracy of 89.2% (25/28) [41]. SRS scintigraphy may be useful both in the staging and
monitoring of patients with WBS-negative DTC metastases. 68Gallium-somatostatin
analogs PET/CT is currently a promising method to study well-differentiated neuroen‐
docrine tumor which has a better sensitivity and therefore is superior to 99mTc or 111In
labeled SRS [63, 64]. SRS scan positive patients are potential candidates for SRS-targeted
therapy.
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In addition, 68Gallium-somatostatin analogs PET/CT is currently a promising method to
study well-differentiated neuroendocrine tumor which has a better sensitivity and
therefore is superior to 99mTc or 111In labeled SRS [63, 64]. 18F-FLT and 11C-MET may also
have a diagnostic roles in this clinical setting [65].
(6) Fine-needle aspiration (FNA)
FNA biopsy for cytology and Tg measurement in the aspirate fluid is performed for
suspicious lymph nodes >8–10 mm in their smallest diameter. Non-suspicious and small
nodes (<8–10 mm in the smallest diameter) can be monitored with neck ultrasonography
[47]. Ultrasonography guidance aspiration may improve the results of FNA biopsy, in
particular for small lymph nodes and those located deep in the neck. The measurement
of Tg in the FNA biopsy washout fluid (FNAB-Tg) is the more accurate tool to detect DTC
recurrences and metastases in the neck [66, 67]. However, the application of FNA biopsy
Tg is currently hindered by the absence of methodological standardization, a lack of
definite cutoff points, and the ongoing debate regarding its accuracy in nonthyroidec‐
tomized patients, those with elevated serum Tg, and those with circulating TgAb [66, 67].
A Tg concentration in the aspirate fluid between 1 and 10 ng/mL is moderately suspicious
for malignancy [47]; above 10 ng/mL are highly suspicious of DTC metastases [68–70].
In summary, in patients with elevated or rising Tg (>10 ng/mL) or TgAb and no evidence of
disease on neck ultrasonography or WBS (if performed), CT imaging of the neck and chest,
MRI of the neck and abdomen may be considered. 18F-FDG-PET/CT also plays an important
role in the detecting DTC metastases with positive Tg (>10 ng/mL) and negative WBS, and
negative conventional imaging. The result of 18F-FDG-PET/CT is helpful in guiding the
treatment strategy. FNA biopsy and Tg measurement in washout fluid are helpful in the
confirmation of foci detected by 18F-FDG-PET/CT.
3.2. Treatments for Tg-positive and WBS-negative DTC metastases
3.2.1. Empiric 131I treatment
Thyroid hormone withdrawal induces substantial short- and long-term morbidity, decreased
quality of life due to associated hypothyroidism.131I therapy may cause early and late sialoa‐
denitis in up to 30% which can lead to xerostomia, dental caries, and stomatitis [71, 72], with
a majority of patients suffering from significant changes in physical, psychological, and social
well-being [73, 74]. Therefore, the pros and cons of empiric 131I treatment should be well-
balanced justified.
The management of elevated serum Tg and radioiodine-negative scans was outlined by Ma et
al. [3]. Of 438 patients from 16 studies who were treated empirically with 131I for iodine-negative
and Tg-positive DTC disease, 267 (62%) displayed pathological uptakes in the thyroid bed,
lungs, bone, mediastinum and lymph nodes. In studies in which data were available for serum
Tg levels during TSH suppression therapy or TSH withdrawal, 56% (188/337) patients showed
decreased Tg. Of 242 patients from 5 studies who received no specific treatment for iodine-
negative and Tg-positive DTC disease, 44% (106/242) showed spontaneous normalization and




a significant decrease in serum Tg. Thus, high doses of 131I have therapeutic effects if the Tg
level is considered an index of tumor burden, at least in the short term, and could also localize
previously undiagnosed recurrences. Therefore, empiric131I treatment may be justified in high-
risk patients with serum Tg > 10 ng/mL and a negative WBS and FDG-PET scan results [3, 75,
76]. Pulmonary metastases may be found only on post-therapy WBS [77]. In a study of 283
DTC patients treated with 100mCi (3.7 GBq) of 131I, 6.4% had lung and bone metastases detected
after treatment that had been suspected based on high serum Tg alone but had not been
detected after 2mCi (74 MBq) 131I WBS [78].
However, most studies in this area have limited reliability as they lacked control groups and
an adequate follow-up period [3]. Still missing from our knowledge are long-term survival
rates, changes in mass sizes on post-therapy imaging, and radiation-induced side-effects of
131I therapy. Although the tumor burden may be diminished, most patients with negative WBS
and positive Tg are not rendered disease free by 131I therapy [79]. Nearly half of patients with
Tg-positive and WBS-negative DTC show spontaneous normalization and significant reduc‐
tion in serum Tg without any specific treatment, 131I therapy should be individualized
according to the clinical characteristics and imaging features. A five-year follow-up of 29
patients with elevated Tg (>2 ng/mL) and negative 131I WBS found that 24/29 patients showed
Tg decreasing trend without 131I therapy, of whom only one patient recurred; the other 5/29
patients showed a rising trend and all recurred [5].
Therefore, additional diagnostic techniques are strongly recommended for patients with Tg-
positive and WBS-negative metastases. If these diagnostic results are positive, treatment
options such as surgery, external radiotherapy and tumor embolization can be considered.
Empiric 131I therapy is more commonly considered for those with distant metastases or
inoperable local disease. If FDG-PET result is negative, one course of 131I treatment may be
considered in high-risk patients with. Repeated 131I therapy may be given to patients who had
persistent non-resectable DTC metastases and iodine uptake, and there are significant
therapeutic benefits until the lesion has been eradicated or the lesion no longer responds to
treatment. The risk of repeated therapeutic doses of RAI must be balanced against uncertain
long-term benefits. In the case of negative post-therapy WBS, the patient should be considered
to have radioiodine-refractory disease and no further 131I therapy should be administered.
3.2.2. Re-differentiation strategies
(1) Retinoic acids (RA) and lithium
RA are active metabolites of vitamin A able to regulate growth and differentiation of many
cell types by binding to specific nuclear receptors, the RA receptors, and the retinoid X
receptors (RXR) [80]. Lithium increases the residence time of 131I in the thyroid tissue [37,
81, 82]. RA and lithium [82] were used to redifferentiate metastatic DTC and render them
responsive to 131I therapy. However, they only yielded a limited clinical benefit.
(2) Iodine-trapping-related gene transfection
hNIS protein is a membrane glycoprotein that transports iodide ions into thyroid cells.
This process, known as iodine trapping, is stimulated directly by TSH. Other proteins,
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including thyroperoxidase (TPO) and pendrin, also play an important role in the thyroid
metabolism of iodine [83]. Strategies of gene transfection focused on NIS; TPO has been
studied to enhance tumor uptake iodine [84, 85]. Co-transfection of the hNIS and hTPO
genes can lead to longer retention of radio iodine [85]. Targeted NIS gene transfer, by viral
and non-viral vectors, followed by radionuclide 131I, 188Re, 211At therapy, has been recently
suggested for the treatment of advanced or WBS-negative DTC metastases. In thyroid
cells, TSH stimulates NIS synthesis [86]. Therefore, hTSHR transfection was investigated
in FTC-133 thyroid cells, which improved the expression of thyroid-specific molecules
including TSHR, NIS, TPO, and Tg and radioiodide uptake [87, 88]. Iodine-trapping-
related gene transfection has not been used clinically yet.
(3) MAPK kinase inhibitor
Mitogen-activated protein kinase (MAPK) signaling inhibits the expression of thyroid
hormone biosynthesis genes, including the NIS and TPO, which facilitate iodine uptake
and organification, respectively [89, 90]. Inhibition of the MAPK pathway may renew the
therapeutic efficacy of 131I by enhancing uptake in patients with thyroid cancer that is
refractory to 131I [82]. MAPK1-2 inhibitor selumetinib (AZD6244, ARRY-142886), orally
administered at a dose of 75 mg twice daily increased the uptake of 124I in 12 of 20 patients.
Selumetinib enhanced 131I uptake in eight patients with advanced DTC. After 131I treat‐
ment, partial responses were achieved in 5, stable disease in 3. No severe adverse events
were observed [82].
In summary, strategy of re-differentiation of iodine-negative DTC metastases by RA has
limited clinical benefit. Iodine-trapping-related protein transfection remains experimental.
MAPK kinase inhibitor needs to be confirmed in large population.
3.2.3. Multi-targeted kinase inhibitors
Both sorafenib (BAY 43-9006) and lenvatinib are multi-kinase inhibitors with potent activity
against RAF, VEGF receptors, fibroblast growth factor receptors, PDGF receptor, c-KIT and
RET kinases [37, 88, 91]. Sorafenib and lenvatinib are both FDA approved for iodine refractory
DTC metastases [92]. They achieved clinical benefits in terms of partial response of 12.5–38%,
progression-free survival from 9 to 24 months in radioiodine-refractory DTC metastases [37,
91]. The therapeutic effects of other tyrosine kinase inhibitors including sunitinib, imatinib,
vandetanib were also summarized [37] and a dozen ongoing trials currently listed in the
ClinicalTrials.gov database, evaluating 12 kinase-inhibiting drugs [93].
Adverse effects occurred in 98.6% patients receiving sorafenib: the most frequent were hand-
foot skin reactions, diarrhea, alopecia, and rash or desquamation [94].
Selection of a targeted agent should depend on disease trajectory, side effect profile, and goals
of therapy. Kinase inhibitor therapy should be considered in radioiodine-refractory DTC
metastases, rapidly progressive, symptomatic and/or imminently threatening disease not
otherwise amenable to local control using other approaches. Patients who are candidates for
kinase inhibitor therapy should be thoroughly counseled on the potential risks and benefits of
this therapy as well as alternative therapeutic approaches including best supportive care [47].






TSH suppression is considered essential in the treatment of patients with positive Tg and
negative WBS, because TSH is a trophic hormone that can stimulate the growth of cells
derived from thyroid follicular epithelium [45, 95, 96]. Therefore, the recommended TSH
level is below 0.1 mU/L, or slightly below or slightly above the lower reference range [9].
(2) Surgery and stereotactic radiotherapy (SBRT)
Most recurrent DTCs respond well to surgery and SBRT [45, 97]. The isolated skeletal
metastasis of DTC is recommended for surgery or SBRT [9]. Neurosurgery or SBRT is
preferred treatments for solitary brain metastases of DTC [98, 99]. SBRT is considered for
loco-regional recurrence that is not surgically resectable, or with extra-nodal extension or
involvement of soft tissues, in particular in patients with no evidence of distant disease,
but has no role in most patients with resectable lymph node metastases [47].
(3) Chemotherapy
Systematic chemotherapy can be considered for DTC lesions with positive Tg and
negative WBS that are not surgically resectable, not responsive to 131I, not amenable to
EBRT treatment, or not responsive to multi-targeted kinase inhibitors, and have clinically
significant structural disease progression during the last 6–12 months. Two of 49 (3%)
patients with DTC metastases had a response to five chemotherapy protocols [100]. In a
review by Ahuja et al., 38% of patients with thyroid cancer had reduction in tumor mass
to doxorubicin [101]. Combination chemotherapy does not show clear superiority to
doxorubicin therapy alone [102]. Therefore, the traditional chemotherapy has limited
effects on iodine refractory DTC metastases [9, 103].
(4) Other treatments
Other treatments include percutaneous ethanol injection (PEI), radiofrequency, or laser
ablation.
PEI for patients with metastatic DTC in lymph node is promising as a nonsurgical-directed
therapy [104, 105]. Most of the studies limited PEI to patients who had undergone previous
neck dissections and 131I treatment, those who had FNA-proven DTC in the lymph node and
those with no known distant metastases [106]. A general consensus from studies and reviews
is that PEI could be considered in patients who are poor surgical candidates [47]. Radiofre‐
quency ablation has been associated with a mean volume reduction that ranges between
approximately 55–95% [107, 108], and 40–60% complete disappearance of the DTC metastases
in the treatment of recurrent thyroid cancer [108, 109]. More recently, preliminary findings
using ultrasonography-guided laser ablation for treatment of cervical lymph node metastases
have been reported [110].
In summary, true-negative WBS with positive Tg may be due to benign thyroid remnants
(possibly containing thyroiditis) or, rarely, nonthyroidal tissue producing Tg. False-negative
WBS with positive Tg can be caused by a defective of acquired iodine-trapping inactivation;
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dedifferentiation of tumor which can still produce Tg but has lost its iodine-trapping ability;
small dispersed microscopic metastases. Other radioisotopes and additional diagnostic
options play an important role in the ascertainment of patients with negative WBS and Tg-
positive DTC metastases. FDG-PET/CT should be considered in high-risk DTC patients with
negative WBS and positive Tg. If FDG-PET diagnostic results are negative, one course of 131I
treatment may be considered in high-risk patients and individualized. No further 131I therapy
is indicated for patients with a negative post-therapy WBS. The preferred hierarchy of
treatment for Tg-positive and WBS-negative metastases is surgical excision of loco-regional
disease in potentially curable patients, 131I therapy for residual radioiodine-responsive disease,
external beam radiation or other directed treatment modalities such as thermal ablation, TSH
suppression for patients with stable or slowly progressive asymptomatic disease, and systemic
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